Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks psoriasis Drug's Real-World impact on diverse skin types

NCT ID NCT07370766

Knowledge-focused Sponsor: Chronicle Academy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

This study follows 80 adults in Canada with moderate-to-severe psoriasis who are starting the drug tildrakizumab. Researchers want to see how the treatment affects quality of life and skin clearing over one year, especially in people with darker skin tones (Fitzpatrick type III and above). The goal is to understand how well the drug works in real-world settings and to make sure treatment benefits everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with moderate-to-severe psoriasis (PsO) planning to initiate treatment with tildrakizumab and meet Fitzpatrick scale skin type III or above. Patients that are either naïve to PsO treatment with a biologic or those who have previously been exposed to a biologic PsO treatment will be eligible for the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 18 years or older. 2. Diagnosis of moderate-to-severe chronic plaque-type PsO with Fitzpatrick scale type III or above (BSA \>/=3%). 3. Candidate for phototherapy and/or systemic therapy. 4. Planning to initiate tildrakizumab as part of routine clinical care through the ILUMYA SUPPORT® Program for the treatment of plaque PsO but has not yet received their first dose. a. Decision to treat with tildrakizumab must be made independently of and prior to study recruitment. 5. Must be able to read, understand, and communicate in English. 6. Must be willing to participate in the study and capable to provide informed consent 7. Able to comply with all study procedures and attend all study visits Exclusion Criteria: 1. Known hypersensitivity to tildrakizumab, its excipients, or components of the container, as outlined in the Product Monograph. 2. Concurrently taking any oral medication for treatment of PsO (e.g. methotrexate, cyclosporin, acitretin) 3. Diagnosis of only palmoplantar psoriasis 4. Concurrent medical condition or significant comorbidities that, in the investigator's opinion, would prevent participation in the study or interfere with study assessments 5. Women of childbearing potential who are pregnant, planning to become pregnant, or breastfeeding. 6. Prior (within 30 days) or actively participating in other interventional clinical trial(s). 7. Unable or unwilling to comply with study procedures including completing questionnaire. 8. Any other condition that, in the opinion of the investigator, could create a hazard to the participant's safety, endanger the study procedures, or interfere with the interpretation of study results

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Moderate to severe psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Moderate to severe psoriasis Psoriasis (PSO)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    7 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Benchmark Dermatology

    RECRUITING

    Burlington, Ontario, L7L 3E5, Canada

  • Elevate Dermatology

    RECRUITING

    Pickering, Ontario, Canada

  • Factor Dermatology

    RECRUITING

    Ottawa, Ontario, K2A 3Z3, Canada

  • Locke Dermatology

    RECRUITING

    Hamilton, Ontario, L8P 4B4, Canada

  • Panorama Dermatology Clinic

    RECRUITING

    Kanata, Ontario, K2T 0N7, Canada

  • Saskatoon Dermatology Centre

    RECRUITING

    Saskatoon, Saskatchewan, S7T0G3, Canada

    Contact Email: •••••@•••••

  • Vital Medical Centre

    RECRUITING

    Ottawa, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.